Clinical Trial

Recombinant Human Thyroid Stimulating Hormone for Radioiodine 131I Treatment

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 8, 2024 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
Subjects: patients with postoperative local recurrent or metastatic differentiated thyroid cancer . Experimental group: Recombinant human thyroid stimulating hormone injection: 0.9mg/1.0mL/piece; intramuscular injection; once a day for two consecutive days. Control group: Thyroid hormone withdraw for 4-6 weeks. The two groups were treated with radioiodine 131I after plasma thyroid stimulating hormone elevated (\>30mU/L). The efficacy and adverse reactions were observed.
Trial Details
NCT Number NCT06405217
Lead Sponsor Nanjing First Hospital, Nanjing Medical University
Conditions DTC - Differentiated Thyroid Cancer, Thyroid Stimulating; Hormone, C, Radiotherapy; Complications
Enrollment 30 participants
Start Date 2024-04-20
Primary Completion 2026-03-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-05-08